Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 12/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10113565 | 0.89 | CNR2 (0.45) | HDAC6ALDH1A1CNR1CNR2 | |
| SCHEMBL10113844 | 0.86 | HDAC3 (0.48) | HDAC3HDAC1HDAC6ALDH1A1NCOR2 | |
| SCHEMBL10113571 | 0.84 | MAPT (0.50) | ALDH1A1 | |
| SCHEMBL13564906 | 0.84 | LMNA (0.39) | ALDH1A1 | |
| SCHEMBL10113497 | 0.83 | L3MBTL1 (0.58) | ALDH1A1CNR1CNR2 | |
| SCHEMBL10113560 | 0.82 | THRB (0.53) | ALDH1A1CNR1CNR2 | |
| SCHEMBL10113603 | 0.77 | CYP2D6 (0.45) | CNR1CNR2 | |
| SCHEMBL10113595 | 0.77 | EPHX2 (0.57) | HDAC3HDAC1HDAC6CNR2 | |
| SCHEMBL10113611 | 0.77 | GAA (0.45) | ALDH1A1CNR1CNR2 | |
| SCHEMBL10113563 | 0.76 | ALDH1A1 (0.47) | HDAC6ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | HDAC3 664/4885HDAC1 1995/4885HDAC6 1853/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | HDAC3 489/4885HDAC1 1703/4885HDAC6 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.